Literature DB >> 1991293

Radiation therapy in metastatic spinal cord compression. A prospective analysis of 105 consecutive patients.

E Maranzano1, P Latini, F Checcaglini, S Ricci, B M Panizza, C Aristei, E Perrucci, S Beneventi, E Corgna, M Tonato.   

Abstract

One hundred thirty consecutive patients with metastatic spinal cord compression (MSCC) were entered in a therapeutic protocol in which radiation therapy (RT) played the main role. When MSCC is diagnosed by clinical-radiologic methods such as myelography with or without computed tomography (CT) or magnetic resonance imaging (MRI), steroids are given and RT treatment started within 24 hours. When diagnostic doubts exist or stabilization is necessary, surgery precedes RT. Chemohormonal potentially responsive tumors are also treated with chemotherapy or hormonal therapy. Twelve patients (9.2%) underwent surgery plus RT, and 118 (90.8%) received RT alone. Thirteen (11%) early death patients were not evaluable. The 105 evaluable cases that received RT alone were analyzed. Median follow-up was 15 months (range, 4 to 38 months). Response among patients with back pain was 80%. In cases with motor dysfunction, 48.6% improved, and in 33 of 105 patients (31.4%) without motor disability there was no deterioration. Forty percent of patients with autonomic dysfunction responded to RT. Median survival time was 7 months with a 36% probability of survival for 1 year. The median duration of improvement was 8 months. The most important prognostic factor was early diagnosis. Radiosensitivity of tumor was only important in paraparetic patients in predicting response to RT. Complete myelographic block significantly diminished response to RT. Vertebral collapse did not influence response or survival.

Entities:  

Mesh:

Year:  1991        PMID: 1991293     DOI: 10.1002/1097-0142(19910301)67:5<1311::aid-cncr2820670507>3.0.co;2-r

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  15 in total

Review 1.  Malignant spinal cord compression.

Authors:  Madhuri Yalamanchili; Glenn J Lesser
Journal:  Curr Treat Options Oncol       Date:  2003-12

2.  Early diagnosis and treatment of spinal epidural metastasis in breast cancer: a prospective study.

Authors:  W Boogerd; J J van der Sande; R Kröger
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-12       Impact factor: 10.154

3.  Paraplegia of spinal epidural compression by metastatic breast cancer and urgent radiotherapy-timeliness for naught?

Authors:  Federico L Ampil; Roxana Baluna; Gary Burton; Anil Nanda
Journal:  J Neurooncol       Date:  2009-04-18       Impact factor: 4.130

4.  Defunctioning stoma in high ASA grade, aged patients, with bowel occlusion due to advanced cancer: is it still worthwhile?

Authors:  Corrado R Asteria; Gabriella Nesi; Chiara Minari; Paolo Viganò
Journal:  Support Care Cancer       Date:  2009-12-13       Impact factor: 3.603

Review 5.  The use of radiation in the management of spinal metastases.

Authors:  C M Faul; J C Flickinger
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

6.  Recurrent spinal epidural metastases: a prospective study with a complete follow up.

Authors:  J J van der Sande; W Boogerd; R Kröger; A C Kappelle
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-05       Impact factor: 10.154

7.  Spine radiosurgery for spinal cord compression: the radiation oncologist's perspective.

Authors:  William F Regine; Samuel Ryu; Eric L Chang
Journal:  J Radiosurg SBRT       Date:  2011

Review 8.  Metastasis to nervous system: spinal epidural and intramedullary metastases.

Authors:  Melike Mut; David Schiff; Mark E Shaffrey
Journal:  J Neurooncol       Date:  2005-10       Impact factor: 4.130

9.  Metastatic spinal cord compression--options for surgical treatment.

Authors:  J D Rompe; P Eysel; C Hopf; J Heine
Journal:  Acta Neurochir (Wien)       Date:  1993       Impact factor: 2.216

10.  Treatment of metastatic spinal cord compression: cepo review and clinical recommendations.

Authors:  S L'espérance; F Vincent; M Gaudreault; J A Ouellet; M Li; A Tosikyan; S Goulet
Journal:  Curr Oncol       Date:  2012-12       Impact factor: 3.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.